On December 4, 2014, the list of the "50 Most Investment-Valuable Companies in China—9th Edition," organized by Qichuang Group, was solemnly announced. Beijing Northland Biotechnology Co., Ltd. was honored with the title of "50 Most Investment-Valuable Companies in China—9th Edition."

Since its inception in 2006, the “Top 50 Most Investment-Valuable Chinese Enterprises” selection event has been successfully held for nine consecutive sessions. Organized and judged by the industry’s most influential VC firms, this event serves as the premier platform for investors to identify high-quality small and medium-sized enterprises with the greatest investment potential. Previous winners—including Qihoo 360, SoftTech, JD.com, and Jumei Youpin—have all demonstrated sustained fundraising capabilities and achieved robust business growth.

This time, our company’s inclusion in the “Top 50 Most Investment-Valuable Enterprises in China—9th Edition” fully reflects the industry’s recognition of our company’s corporate value and its endorsement of our development prospects. In the future, Beijing NORTHLAND will leverage the recognition from the capital market to increase investment in scientific research, accelerate the industrialization of research findings, and make positive contributions to the development of China’s biopharmaceutical industry while generating both excellent economic and social benefits!